On the metabolism of haloperidol

References

• Ashby C. R., Jr, Hitzemann R., Rubinstein J. E., Wang R. Y. One year treatment with haloperidol or clozapine fails to alter neostriatal D1- and D2-dopamine receptor sensitivity in the rat. Brain Research 1989; 493: 194–197
   PubMedGoogle Scholar
• Baldessarini R. J., Tarsy D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annual Reviews in Neuroscience 1980; 3: 23–41
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Gorrod J. W., Jenner P. The analysis of nicotine-1′-N-oxide in urine, in the presence of nicotine and cotinine, and its application to the study ofin vivo nicotine metabolism in man. Journal of Pharmacy and Pharmacology 1971; 23: 55–61
   Web of Science ®Google Scholar
• Casy D. E. Psychopharmacology. The Third Generation of Progress. New York, Raven 1987; 1411–1418
   Google Scholar
• Dom R. Local glial reaction in the CNS of albino-rats in response to the administration of a neuroleptic drug (Butyrophenone). Acta Neurologia Belgica 1967; 67: 755–762
   Google Scholar
• Fang J., Gorrod J. W. Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicology Letters 1991; 59: 117–123
   PubMed Web of Science ®Google Scholar
• Fang J., Gorrod J. W. Metabolism of haloperidol by mouse hepatic microsomal preparations. Medical Science Research 1992; 20: 175–177
   Google Scholar
• Fang J., Gorrod J. W. An h.p.l.c. method for the detection and quantitation of haloperidol and seven of its metabolites. Journal of Chromatography 1993, in press
   PubMedGoogle Scholar
• Fang J., Gorrod J. W., Kajbaf M., Lamb J., Naylor S. Investigation of the neuroleptic drug haloperidol and its metabolites using tandem mass spectrometry. International Journal Mass Spectrometry Ion Processes 1992, in press
   PubMedGoogle Scholar
• Forsman A., Larsson M. Metabolism of haloperidol. Current Therapeutic Research 1978; 24: 567–568
   Web of Science ®Google Scholar
• Forsman A., Ohman R. On the pharmacokinetics of haloperidol. Nordisk Psykiatrisk Tidsskrift 1974; 28: 441–448
   Google Scholar
• Gorrod J. W. Extra-hepatic metabolism of drugs. Drug Metabolism in Man, J. W. Gorrod, A. H. Beckett. Taylor & Francis Ltd., London 1978; 157–174
   Google Scholar
• Gorrod J. W., Temple D. J., Beckett A. H. The metabolism ofN-ethyl-N-methylaniline by rabbit liver microsomes: the measurement of metabolites by gas-liquid chromatography. Xenobiotica 1975; 5: 453–463
   PubMed Web of Science ®Google Scholar
• Grohmann R., Koch R., Schmidt L. G. Extrapyramidal symptoms in neuroleptic recipients. Adverse Drug Reactions. Birkhauser Verlag, Basel 1990; 71–82
   Google Scholar
• Janssen P. A. J., Allewijn F. T. The distribution of the butyrophenones haloperidol, trifluperidol, moperone and clofluperdol in rats, and its relationships with their neuroleptic activity. Arzneimittel Forschung 1969; 19: 199–208
   PubMedGoogle Scholar
• Jiang L. H., Kasser R. J., Altar C. A., Wang R. Y. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists. Journal of Pharmacology and Experimental Therapeutics 1990; 253: 1198–1205
   PubMed Web of Science ®Google Scholar
• Kirch D. G., Palmer M. R., Egan M., Freedman R. Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain. Neuropharmacology 1985; 24: 375–379
   PubMedGoogle Scholar
• Koizumi J., Shiraishi H. Synaptic changes in the rabbit pallidum following long-term haloperidol administration. Folia Psychiatrica Neurologica Japonica 1973; 27: 51–57
   PubMedGoogle Scholar
• Kornhubner J., Riederer P., Reynolds G. P., Beckmann H., Jellinger K., Gabriel E. 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. Journal of Neural Transmission 1989; 75: 1–10
   PubMedGoogle Scholar
• Korpi E. R., Costakos D. T., Wyatt R. J. Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochemical Pharmacology 1985; 34: 2923–2927
   PubMed Web of Science ®Google Scholar
• Meshul C. K., Casey D. E. Regional, revesible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Research 1989; 489: 338–346
   PubMed Web of Science ®Google Scholar
• Mesnil M., Testa B., Jenner P. Xenobiotic metabolism by brain monooxygenases and other cerebral enzymes. Advances in Drug Research 1984; 13: 95–207
   Google Scholar
• Midha K. K., Hawes E. M., Hubbard J. W., Korchinski E. D., McKay G. Interconversion between haloperidol and reduced haloperidol in humans. Journal of Clinical Psychopharmacology 1987; 7: 362–364
   PubMed Web of Science ®Google Scholar
• Oida T., Terauchi Y., Yoshida K., Kagemoto A., Sekine Y. Use of antisera in the isolation of human specific conjugates of haloperidol. Xenobiotica 1989; 19: 781–793
   PubMed Web of Science ®Google Scholar
• See R. E., Ellison G. Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rat. Psychopharmacology 1990; 100: 404–412
   PubMedGoogle Scholar
• Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133–152
   PubMed Web of Science ®Google Scholar
• Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell menbrances. Journal of Clinical Psychopharmacology 1988; 8: 35–95, Suppl. 4
   Google Scholar
• Soudijn W., Van Wijngaarden I., Allewijn F. Distribution, excretion and metabolism of neuroleptics of the butyrophenone type: part I. excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the wistar rat. European Journal of Pharmacology 1967; 1: 47–57
   PubMedGoogle Scholar
• Subramanyam B., Rollema H., Woolf T., Castagnoli N., Jr. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochemistry and Biophysics Research Communications 1990; 166: 238–244
   PubMed Web of Science ®Google Scholar
• Subramanyam B., Woolf T., Castagnoli N., Jr. Studies on thein vitro conversion of haloperidol to a potentially neurotoxic puridinium metabolite. Chemical Research Toxicology 1991; 4: 123–128
   PubMed Web of Science ®Google Scholar
• Waddington J. L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 1990; 101: 431–447
   PubMed Web of Science ®Google Scholar
• Wu E., Shinka T., Caldfra-Munoz P., Yoshizumi H., Trevor A., Castagnoli N., Jr. Metabolic studies on the nigrostriatal toxin MPTP and its MAO-B generated dihydropyr-idinium metabolite MPDP+. Chemical Research Toxicology 1988; 1: 186–194
   PubMed Web of Science ®Google Scholar
• Zingales I. A. A gas chromatographic method for the determination of haloperidol in human plasma. Journal of Chromatography 1971; 54: 15–24
   PubMed Web of Science ®Google Scholar